Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qigui Yishen Prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by the First Affiliated Hospital of Soochow University. It is primarily investigated for its potential to mitigate and delay the progression of acute and chronic kidney diseases, particularly those induced by platinum-based chemotherapy agents such as cisplatin. The prescription typically contains *Astragalus membranaceus* (Huangqi) and *Angelica sinensis* (Danggui), which are traditionally used in TCM to tonify Qi and enrich blood while specifically targeting kidney health. In clinical settings, it is used in combination with Western medical protocols to provide a synergistic effect in preserving renal function, reducing nephrotoxicity, and managing chronic renal failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qigui Yishen Prescription (First Affiliated Hospital of Soochow University).